Marcus Schulz - 31 Mar 2023 Form 4/A - Amendment Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
Chief Revenue Officer
Signature
/s/ Marcus Schulz
Issuer symbol
BLFS
Transactions as of
31 Mar 2023
Net transactions value
-$15,443
Form type
4/A - Amendment
Filing time
16 May 2023, 21:48:30 UTC
Date Of Original Report
10 Apr 2023
Previous filing
03 Mar 2023
Next filing
10 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise +2,912 +6.9% 45,390 31 Mar 2023 Direct F1
transaction BLFS Common Stock Sale $15,443 -771 -1.7% $20.03 44,619 06 Apr 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Restricted Stock Award Options Exercise $0 -2,912 -100% $0.000000* 0 31 Mar 2023 Common Stock 2,912 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F2 The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
F3 This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,912 shares.